Latest UCB Stories
ATLANTA, Nov. 9, 2010 /PRNewswire/ -- UCB (EURONEXT: UCB) and U.S. based partner Immunomedics Inc.
ATLANTA, Nov. 2, 2010 /PRNewswire/ -- UCB, a global biopharmaceutical company long recognized for its commitment to the epilepsy community and patient-centered approach, will mark Epilepsy Awareness Month by rolling out new activities and resources at the national and local levels.
ATLANTA, Oct. 14 /PRNewswire/ -- UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Crohn's and Me Scholarship Program for outstanding individuals affected by this condition.
ATLANTA, Sept. 28 /PRNewswire/ -- UCB today announced the first installment of the Crohn'sAdvocate(TM) Online Forum Series, a succession of interactive programs designed to connect, educate and empower those who are affected by Crohn's disease.
BRUSSELS, July 28 /PRNewswire/ -- UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that NeuproÂ® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS).
ATLANTA, June 29 /PRNewswire/ -- New long term data showed that VimpatÂ® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy.
BRUSSELS, June 18 /PRNewswire-FirstCall/ -- The first data to show that NeuproÂ® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.
ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE).